Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) closed the day trading at $12.78 down -3.03% from the previous closing price of $13.18. In other words, the price has decreased by -$3.03 from its previous closing price. On the day, 8.96 million shares were traded. TEVA stock price reached its highest trading level at $13.21 during the session, while it also had its lowest trading level at $12.75.
Ratios:
For a better understanding of TEVA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.18. For the most recent quarter (mrq), Quick Ratio is recorded 0.69 and its Current Ratio is at 1.02. In the meantime, Its Debt-to-Equity ratio is 2.70 whereas as Long-Term Debt/Eq ratio is at 2.46.
On February 12, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $12 to $19.
Jefferies Upgraded its Hold to Buy on January 23, 2024, whereas the target price for the stock was revised from $10 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’24 when Kalif Eliyahu Sharon sold 77,550 shares for $13.52 per share. The transaction valued at 1,048,119 led to the insider holds 203,691 shares of the business.
Sabag Mark sold 100,000 shares of TEVA for $1,352,090 on Mar 05 ’24. The EVP, International Markets now owns 382,590 shares after completing the transaction at $13.52 per share. On Mar 05 ’24, another insider, Daniell Richard, who serves as the Exec. VP, European Commercial of the company, sold 48,629 shares for $13.52 each. As a result, the insider received 657,240 and left with 69,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TEVA now has a Market Capitalization of 14475139072 and an Enterprise Value of 31994580992. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.90 while its Price-to-Book (P/B) ratio in mrq is 1.91. Its current Enterprise Value per Revenue stands at 2.019 whereas that against EBITDA is 7.384.
Stock Price History:
Over the past 52 weeks, TEVA has reached a high of $14.47, while it has fallen to a 52-week low of $7.09. The 50-Day Moving Average of the stock is -4.71%, while the 200-Day Moving Average is calculated to be 20.42%.
Shares Statistics:
Over the past 3-months, TEVA traded about 10.43M shares per day on average, while over the past 10 days, TEVA traded about 9431470 shares per day. A total of 1.12B shares are outstanding, with a floating share count of 1.12B. Insiders hold about 0.01% of the company’s shares, while institutions hold 52.44% stake in the company. Shares short for TEVA as of 1711584000 were 11555241 with a Short Ratio of 1.11, compared to 1709164800 on 14720314.
Dividends & Splits
The stock’s 5-year Average Dividend Yield is 2.95.
Earnings Estimates
The dynamic stock of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) is currently being evaluated by a team of Teva Pharmaceutical Industries analysts, each contributing to its current rating.The consensus estimate for the next quarter is $3.10, with high estimates of $19.16 and low estimates of $0.40.
Analysts are recommending an EPS of between $Technology and $Basic Materials for the fiscal current year, implying an average EPS of $Technology.
